Stock LSB LAKESHORE BIOPHARMA CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

News LakeShore Biopharma Co., Ltd

Equities

LSB

KYG9845F1090

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
0.6977 USD +0.93% Intraday chart for LakeShore Biopharma Co., Ltd -8.20% +36.54%
Jun. 10 Lakeshore Biopharma Co., Ltd Announces Executive Changes CI
May. 28 YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LakeShore Biopharma : Departure of Directors Form 6 K
PU
Lakeshore Biopharma Co., Ltd Announces Executive Changes
CI
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS
CI
YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28
MT
YS Biopharma Announces Name Change to LakeShore Biopharma
PR
YS Biopharma Announces Results of Extraordinary General Meeting
PR
YS Biopharma Co., Ltd. Approves Board Appointments
CI
YS Biopharma Co., Ltd. has Changed its Name to LakeShore Biopharma Co., Ltd
CI
Ys Biopharma Co., Ltd Announces Executive Changes
CI
YS Biopharma Co., Ltd. Approves the Appointment of Hui Shao as the Chief Business Officer
CI
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
PR
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PR
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
AQ
YS Biopharma Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023
CI
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
PR
YS Biopharma Receives Clinical Trial Approval for Potential Hepatitis B Treatment
MT
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
PR
YS Biopharma Co., Ltd. Grants Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
CI
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
PR
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LSB Stock
  4. News LakeShore Biopharma Co., Ltd